Heron Therapeutics, Inc.

HRTX11 Dec 2024
Healthcare
$1.77
+0.01 (+0.57%)
Lowest Today
$1.71
Highest Today
$1.88
Today’s Open
$1.77
Prev. Close
$1.75
52 Week High
$3.93
52 Week Low
$1.04
To Invest in Heron Therapeutics, Inc.

Heron Therapeutics, Inc.

Healthcare
HRTX11 Dec 2024
+0.01 (+0.57%)
1M
3M
6M
1Y
5Y
Low
$1.71
Day’s Range
High
$1.88
1.71
52 Week Low
$1.04
52-Week Range
52 Week High
$3.93
1.04
1 Day
-
1 Week
+7.31%
1 month return
-4.34%
3 month return
-2.76%
6 month return
-51.51%
1 Year return
+15.4%
3 Years return
-80.36%
5 Years return
-93.12%
10 Years return
-
Institutional Holdings
Rubric Capital Management LP
17.56
Adage Capital Partners Gp LLC
5.82
Vanguard Group Inc
5.73
BlackRock Inc
5.47
Velan Capital Investment Management LP
4.59
Tejara Capital Ltd
3.49
Vanguard Total Stock Mkt Idx Inv
3.08

Market Status

Fundamentals
Market Cap
266.17 mln
PB Ratio
12.6
PE Ratio
0
Enterprise Value
353.75 mln
Total Assets
222.51 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Organisation
Heron Therapeutics, Inc.
Employees
126
Industry
Biotechnology
CEO
Mr. Craig Alexander Collard
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities